A patient-needs driven, not-for-profit research and development organization, Drugs for Neglected Diseases initiative (DNDi) works to deliver
new treatments for neglected diseases, in particular leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, paediatric
HIV, mycetoma, and hepatitis C. Since its inception in 2003, DNDi has delivered six treatments: two fixed-dose antimalarials (ASAQ and ASMQ)—recently
transferred to the Medicines for Malaria Venture; nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness; sodium stibogluconate
and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa; a set of combination therapies for visceral leishmaniasis in
Asia; and a pediatric dosage form of benznidazole for Chagas disease. DNDi has established regional disease-specific platforms, which bring
together partners in disease-endemic countries to strengthen existing clinical research capacity, as well as to build new capacity where necessary.